Legal Battle Between UCSD, USC Continues

The University of Southern California countersues the University of California, San Diego, as a pharmaceutical company ends an Alzheimer’s research–related contract with the latter institution.

Written byBob Grant
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

The George Finley Bovard building on the campus of USCWIKIMEDIA, BRION VIBBERThe legal dispute between the University of Southern California (USC) and the University of California, San Diego (UCSD), is showing no signs of resolution. Last month (August 24), a San Diego Superior Court Judge issued a preliminary injunction that would force USC to cede control of a multi-million-dollar Alzheimer’s project that a former UCSD researcher took with him when he moved institutions. And as the two sides await the formal court order granting the injunction, USC countersued UCSD for trying to intimidate researchers who also wanted to leave UCSD for USC with principal investigator Paul Aisen, among other allegations.

“The University of Southern California’s cross-complaint is fundamentally dishonest,” UCSD said in a statement. “It is a collection of misstatements and outright falsehoods designed to distract from a singular truth: While he was on the faculty at UC San Diego, Dr. Paul Aisen, aided and abetted by his future employer USC, illegally seized control of data and computer systems that belong to UC San Diego as the administrator of the Alzheimer’s Disease Cooperative Study (ADCS).”

In its countersuit, USC is claiming that UCSD tried to force Aisen to sign an oath of loyalty prior to his departure from UCSD to USC in June. The suit also alleges that UCSD defamed Aisen by telling pharmaceutical industry sponsors of ADCS that Aisen had committed crimes and was ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

    View Full Profile
Share
Image of a woman with her hands across her stomach. She has a look of discomfort on her face. There is a blown up image of her stomach next to her and it has colorful butterflies and gut bacteria all swarming within the gut.
November 2025, Issue 1

Why Do We Feel Butterflies in the Stomach?

These fluttering sensations are the brain’s reaction to certain emotions, which can be amplified or soothed by the gut’s own “bugs".

View this Issue
Golden geometric pattern on a blue background, symbolizing the precision, consistency, and technique essential to effective pipetting.

Best Practices for Precise Pipetting

Integra Logo
Olga Anczukow and Ryan Englander discuss how transcriptome splicing affects immune system function in lung cancer.

Long-Read RNA Sequencing Reveals a Regulatory Role for Splicing in Immunotherapy Responses

Pacific Biosciences logo
Research Roundtable: The Evolving World of Spatial Biology

Research Roundtable: The Evolving World of Spatial Biology

Conceptual cartoon image of gene editing technology

Exploring the State of the Art in Gene Editing Techniques

Bio-Rad

Products

Labvantage Logo

LabVantage Solutions Awarded $22.3 Million U.S Customs and Border Protection Contract to Deliver Next-Generation Forensic LIMS

The Scientist Placeholder Image

Evosep Unveils Open Innovation Initiative to Expand Standardization in Proteomics

OGT logo

OGT expands MRD detection capabilities with new SureSeq Myeloid MRD Plus NGS Panel